Categories
- Active Surveillance
- Announcements
- Ask Dr. Barken
- Biomarker
- Biopsy
- Bone Metastases
- Brachytherapy
- Cancer Stem Cells
- Castration Resistant Prostate Cancer
- CETC
- Checklist
- Choline 11 PET Scan
- Clinical Trials
- Coaching
- Color Doppler Trans-Rectal Ultrasound
- Cryo Immunotherapy
- Cryoablation
- CTC
- Decision Making
- Diagnosis
- Exosome
- Ferumoxytol
- Focal Therapy
- Genome
- HIFU
- High Intensity Foucused Ultrasound
- Hormonal Blockade
- Hormone Refractory Disease
- Imaging
- Immune Therapy
- Intermittent Hormonal Blockade
- Journal Club
- Laser
- LIfe Style
- Liquid Biopsy
- Lymph Nodes
- Markers
- Metastatic Disease
- Metastatic Prostate Cancer Disease
- MRI
- MRI Guided Focal
- Multi Parameteric MRI
- Nutrition
- PCREF Support Group Meeting
- PET scans
- Photodynamic Therapy
- Prevention
- Prognosis
- Prostate Cancer
- PSA
- Radiation Therapy
- Radiation treatment
- Radical Prostatectomy
- Sequential Hormonal Blockade
- Sexual Dysfunction
- Support for Prosatate Cancer
- Survival prostate cancer
- Testosterone
- Theranostics
- Treatments for Prostate Cancer
- Tumor Spheres
- Uncategorized
- Vaccine
Category Archives: Metastatic Disease
Enzalutamide monotherapy in Hormone-Naïve Prostate Cancer
Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer.
Cryo Immunotherapy Part 1
Dr. Barken presents the history of cryoablation and the new developments in the field of immunology which will create enhancement of the Immune effect on metastatic disease in response to cryoablation of local tumor.
OligoMetastatic Prostate Cancer – Lecture by Eugene Kwon M.D.
Eugene Kwon M.D. at the PCRI 2014 Annual Meeting. Topic : OligoMetastatic Prostate Cancer Disease. Dr. Kwon brings examples of Choline 11 PET scans as a tool to find location of metastatic lesions. These targets can be treated and also watched … Continue reading →
Circulating Epithelial Tumor Cells
Interview with Peter Pachmann about Mmaintrac Click here to send a video question and you will get an e mail video reply
Posted in Biomarker, CETC, CTC, Diagnosis, Metastatic Disease, Treatments for Prostate Cancer
|
Leave a comment
Phase III Prostvac Clinical Study
Immune Therapy is an important tool for advanced prostate cancer disease, especially in older patients for whom chemotherapy is excluded because of other serious medical problems. Dr. Barken presents the Prostvac Clinical Study Phase III with a video clip featuring … Continue reading →
Treatment options post Taxotere
Question of the week: What’s available after Taxotere for a patient with bone metastatic disease? Dr. Barken talks to a caller about his options for treatment after chemotherapy. For the Ask Dr Barken Call In Show on Tuesday, Dec. 18th at 6pm … Continue reading →
Early Immune Therapy
For the Ask Dr Barken Call In Show on Tuesday, Nov. 27th at 6pm Pacific Dial 1-877-727-3301 to hear the program and speak with Dr. Barken. You may leave a question before the show by dialing the same number and recording … Continue reading →
Continuous versus Intermittent Hormonal Blockade Study
Continuous versus Intermittent Hormonal Blockade. Are survival outcomes equal? Ask Dr Barken Call In Show- Every Tuesday 6PM Pacific Time. Call In and talk live with Dr. Barken.
Noscapine availability and avoiding gynecomastia
Questions Called in to the Ask Dr. Barken Show: 1. Where can I get Noscapine in the United States? 2. For patients on Sequential Androgen Blockade, what is Dr. Barken’s common sense approach to avoiding Gynecomastia? Dr. Barken answers two … Continue reading →